datopotamab,Pembrolizumab,Carboplatin,Cisplatin
Daiichi Sankyo,merck,AstraZeneca
['pembro', 'tropion,lung02', 'tropion,lung,8', 'sclc', 'lung', 'tropion,lung,02', 'lcsm,(-blcsm)', 'nsclc', 'tropion,lung,2']
tropion-lung02 is on! ph1b dato-dxd + pembro +/- chemo in nsclc. orr 38/49% in all patients, 50/57% in 1l. mdor not reached in any group. toxicity is still a concern (mielotoxicity) a great way ahead of the combination. 1l ph3 will be an exciting trial! #asco23 #lcsm 
Husband, Father. Medical Oncologist and Researcher focused in Thoracic Oncology.  Views are my own. Member of @latenightonc - the best podcast in oncology!